

Catalog# BP-50543

Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody

Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.

| Product Details | |
|------------------------|---|
| CAS No. | 477202-00-9 |
| Species Reactivity | Human |
| Source | Ipilimumab biosimilar CHO stable cell line |
| Isotype | Human IgG1 kappa |
| Class | Monoclonal |
| Type | Antibody |
| Clone | Ipilimumab Biosimilar |
| Conjugate | Unconjugated |
| Immunogen | Human CTLA4 |
| Purity | >95% |
| Molecular Weight | 145.38 kDa |
| Protein Concentration | 1 mg/ml |
| Formulation | 0.2 μ M filtered PBS solution, pH 7.4 |
| Storage conditions | 4°C for short time, -20°C or -80°C for long time. |